This article provides an update on the appropriate diagnosis and evaluation of patients with tension-type headache, with reviews of the latest concepts regarding pathogenesis and the evidence-based recommendations for management of this disorder. Recent Findings: Pericranial myofascial mechanisms are probably of importance in episodic tension-type headache, whereas sensitization of central nociceptive pathways and inadequate endogenous antinociceptive circuitry seem to be more relevant in chronic tension-type headache. While acute treatment with simple analgesics is generally helpful, recent data attempting to document the efficacy of preventive therapies are unconvincing. Summary: Tension-type headache is the most common form of headache in the general population. It is characterized by recurrent episodes of headache that are relatively featureless and mild to moderate in intensity. The diagnosis is based solely on the history and examination. Exclusion of secondary headaches or forms of migraine is important in the assessment process. Despite extensive investigation, the underlying pathophysiology remains a matter of speculation, with peripheral muscular and CNS components both likely involved. Acute management with simple analgesics, nonsteroidal anti-inflammatory drugs, and caffeine-containing compounds is typically effective. Preventive therapies include a number of nonpharmacologic recommendations as well as several antidepressant drugs. Prognosis is generally favorable.
CLASSIFICATION AND DESCRIPTION
Tension-type headache (TTH) is an illdefined and likely heterogeneous syndrome. Subclassified according to frequency, the International Classification of Headache Disorders, Second Edition (ICHD-II) recognizes infrequent episodic (averaging less than 1 day per month), frequent episodic (averaging 1 to 14 days per month), and chronic (averaging more than 14 days per month) subtypes ( Table 6 -1). 1 The phenotypic features are nonspecific, and diagnostic criteria are based more on what it is not rather than what it is. By definition these headaches involve pain that is not localized, not throbbing, not aggravated by activity, and not severe. Associated neurologic, auto-nomic, or migrainous features are not components of this disorder. There is no significant nausea, no vomiting, and photophobia and phonophobia cannot both be present. The ICHD-II also allows for further subclassification based on the presence or absence of pericranial muscle tenderness. Finally, the diagnosis requires the exclusion of secondary headache possibilities.
In episodic tension-type headache (ETTH) the attacks typically last anywhere from 30 minutes to 7 days, whereas those with chronic tensiontype headache (CTTH) may report discomfort of a relatively continuous nature. Most episodes develop during waking hours, and progression over the course of the day is common. Nocturnal development of TTH is uncommon and should provoke further investigation. The most frequently reported triggers for TTH are mental or physical stressors, which explains why the term ''tension-type'' headache has been retained in the most recent classification and also why TTH was previously known as ''stress'' and ''muscle contraction'' headache. Other commonly described triggers include hunger, dehydration, overexertion, alterations in sleep patterns, caffeine withdrawal, and female hormonal fluctuations. 2 
DIAGNOSIS AND INVESTIGATION
The phenotypic features of TTH are nonspecific and may be seen with an assortment of secondary headache con-ditions that are linked mechanistically to an identifiable structural or physiologic disorder. 3 A fundamental criterion to establish a link between an apparent organic condition and headache is the resolution or amelioration of symptoms following treatment of the underlying disorder. Ranging from benign to catastrophic, these conditions frequently present with phenotypic headaches similar to tension-type headaches. Intracranial mass lesions (eg, tumor, subdural hematoma), disorders of CSF pressure (eg, benign intracranial hypertension, hydrocephalus), joint dysfunction of the cervical spine or temporomandibular joint, and systemic conditions (eg, giant cell arteritis, KEY POINT h Tension-type headache is subclassified by frequency of headache occurrences. Infrequent episodic tension-type headache occurs less frequently than 1 day per month, frequent episodic tension-type headache between 1 and 14 days per month, and chronic tension-type headache 15 days or more per month. obstructive sleep apnea, hypothyroidism) may all present with apparent tension-type headache. Although symptoms may be shared with primary headaches, patients with secondary headaches often exhibit one of the ''red flags'' that may signify organic underpinnings ( Table 6 -2). 4 Because of this extensive symptom overlap between primary and secondary headaches, it is crucial to elicit the temporal pattern of the headache disorder during clinical assessment. Headaches described as ''new'' or ''different,'' as well as those that progress in frequency or intensity, should raise particular concern. Thorough general and neurologic examinations are key components to the clinical evaluation and can provide clues to the potential presence of organic disease. In those patients where such suspicions are raised by the history or examination, further diagnostic workup might include neuroimaging of the brain or cervical spine, CSF analysis, or serum testing with erythrocyte sedimentation rate and thyroid function studies. 5 The difficulty in distinguishing ETTH from migraine headache, two of the most common episodic headache types, is widely acknowledged 6 (Case 6-1). Individuals with episodic migraine often describe milder attacks that may be suggestive of ETTH, and often an acute migraine passes through a milder initial phase that may be misinterpreted initially as a tension-type attack. Both of these factors contribute to a high rate of misdiagnosis. Clinicians are likely to diagnose TTH when bilateral or nonthrobbing head pain is present, when a patient reports that the headache is triggered by stress or muscle tension, or when neck pain is present, yet all these features are common with migraine. Among respondents in the American Migraine Study II who met ICHD criteria but lacked a physician diagnosis of migraine, 32% reported a physician diagnosis of TTH. 7 In one study investigating the efficacy of sumatriptan for the range of headaches experienced by people with migraine, 71% of patients initially diagnosed with ETTH had their diagnosis altered to migraine after a detailed review of diary data. 8 Another study demonstrated that 84% of those in the population with self-diagnosed ''stress'' or ''tension'' headaches actually met criteria for migraine. Such diagnostic confusion is not limited to those with episodic headache conditions. 9 Patients with chronic migraine often describe a lower-grade headache that is phenotypically similar to CTTH, particularly in the presence of a medication-overuse component. Because more than 90% of patients consulting clinicians for recurrent episodic headache disorders will ultimately be diagnosed with migraine and only 3% will be diagnosed with TTH, it is imperative to exclude migraine as a possibility before arriving at a TTH diagnosis. 10 
EPIDEMIOLOGY OF TENSION-TYPE HEADACHE
TTH is the most common primary or secondary headache, with prevalence varying by population, subtype of TTH studied, age, and sex. One large population-based survey in the United States determined an annual prevalence of 38.3% for ETTH and 2.2% for CTTH. 11 On the basis of pooled results from five population-based studies, the mean lifetime prevalence of TTH in adults is 46% (range 12% to 78%), and the prevalence for CTTH is fairly consistent worldwide at 2% to 3%. 12 Al-though no clear genetic underpinnings have been identified, approximately 40% of patients report a family history of some form of headache disorder, and first-degree relatives have a twofold to fourfold increased risk of CTTH compared to the general population. Twin studies have shown no difference in risk between identical and nonidentical twins.
The prevalence varies by sex and age. 13 There is a slight female preponderance for ETTH, with a female to male ratio of approximately 5:4, although this ratio increases when the headache disorder becomes chronic. Most develop TTH prior to age 30, with peak prevalence between the ages of 40 and 49 and a subsequent decrease with age in both sexes. 11 Despite such declines, the rates of ETTH remain above 25% in the seventh decade of KEY POINTS h Given the significant symptom overlap, the diagnosis of tension-type headache requires initial consideration and exclusion of secondary headache disorders and migraine headache.
h Tension-type headache is the most prevalent primary headache condition. In the US population, the estimated annual prevalence for episodic tension-type headache is 38.3% and for chronic tension-type headache is 2.2%.
Case 6-1
A 28-year-old woman presented with ''stress headaches.'' She had previously been treated for generalized anxiety but reported no ongoing issues. The headaches dated back to her teens and had increased in frequency and intensity over the past year, coinciding with a job promotion and relocation. She described bilateral attacks of nonpulsating pain that lasted 12 to 24 hours and occurred once or twice weekly. At times the pain reached moderate to severe levels, with some sensitivities to light and noise but no nausea. She experienced significant tightness in her neck before and during the headaches. Her greatest concern was her need for occasional bed rest and associated work absences. General physical and neurologic examinations were normal, and a CT scan performed after a particularly severe episode was also normal.
Comment. This case illustrates the importance of considering other primary and secondary headache syndromes before applying the label of tension-type headache (TTH). The temporal pattern is not particularly worrisome, nor are there any red flags to raise any suspicion for secondary headache pathology. Although the patient describes trigger factors (stress), location (bilateral), and pain (nonpulsating) characteristic of TTH, the appropriate diagnosis in this case would be episodic migraine. By definition episodic TTH never reaches severe levels of disability nor is it associated with both photophobia and phonophobia. Although the presence of neck discomfort commonly leads to a diagnosis of TTH, it is actually quite common in migraine. Because significant overlap exists between TTH and both secondary and migraine headache syndromes, it is imperative to consider these other options before proceeding with a diagnosis of TTH. life for both men and women, and 1.5% of men and 2.7% of women continue to report CTTH beyond age 60. There is also a correlation between prevalence of ETTH and higher educational level.
ETTH is as prevalent as migraine in both children and adolescents. According to estimates from several population-based studies, the mean prevalence in children is 31% (range 10% to 72%). 14 Headaches develop at a mean age of 7, with an average duration of 2 hours. Age is again a risk factor, as the rate of TTH has been shown to rise in schoolchildren between the ages of 7 and 15. For children the duration, frequency, intensity, and medication use associated with attacks of ETTH are typically lower than with episodic migraine. The prevalence of CTTH is lower in children than in adults, and estimates generally place it at less than 1% of this age group. TTH in children and adolescents is also related to psychosocial factors. Such individuals are more likely to report depression, divorced parents, and fewer peer relationships than patients with migraine and headache-free controls. 15 Partly because of its higher population prevalence, the societal impact of TTH is actually greater than that of migraine. 12 A number of studies have documented considerable absenteeism with TTH. One study from the United States demonstrated that both ETTH and CTTH cause significant absenteeism, while another from Europe showed that the number of lost workdays from TTH was 3 times higher than from migraine. The economic and social burdens are higher for those with CTTH than those with ETTH as measured by several disability instruments, including the Migraine Disability Assessment Scale and the General Health Questionnaire. The impact is particularly high for those with comorbid complications, such as depression as measured by the Beck Depression Inventory. Frequency rather than severity of headache appears to have a greater impact on disability and quality of life.
COMORBIDITY OF TENSION-TYPE HEADACHE
TTH is associated with several psychiatric and medical conditions. Although the evidence is more robust for those with migraine, a number of studies have established a relationship between TTH and major depression, generalized anxiety disorder, and panic disorder. 16 Temporomandibular disorders have been linked to both migraine and TTH in several studies, although the relationship may be confounded by the fact that one symptom of temporomandibular dysfunction is headache. Patients with cervical spine discogenic and spondylotic disorders present with features of TTH, and in such patients it may be difficult to distinguish a primary TTH from a secondary ''cervicogenic'' cause based on clinical criteria alone. The best means of mechanistic connection with either temporomandibular joint dysfunction or cervical spine disease is significant improvement or eradication of headache following treatment of the secondary structural disorder. 17 
PATHOPHYSIOLOGY OF TENSION-TYPE HEADACHE
TTH was initially proposed as arising from excessive contraction of pericranial and cervical muscles, leading to the original term ''muscle contraction headache.'' 18 Many believe a link exists between these headaches and emotional distress or ''life tension.'' Environmental influences appear to carry greater importance than genetic factors in the development of TTH. 19 Stress is a widely accepted contributing factor to TTH, but the mechanisms underlying the relationship are unclear. 20 Self-reported inability to relax and poor self-health assessments, in addition to inadequate sleep, have all been reported as additional risk factors likely linked to stress. Irregular nutrition or hydration may act as a trigger, but aside from caffeine, which may trigger TTH through excessive exposure or withdrawal, diet seems to have very little impact. Over the past decade, there have been a number of medications, including female hormonal supplements, may aggravate an underlying tension-type or migraine headache disorder.
The precise cause of TTH remains unknown. An inherent complexity may exist because mechanisms may vary between ETTH and CTTH populations and also between individuals within these subgroups. 21 Over the past decade, there have been a number of insights into the pathophysiologic aspects of TTH. These insights suggest that TTH is a multifactorial process involving both peripheral myofascial factors and CNS components. 22 Pericranial myofascial mechanisms are probably of importance in ETTH, whereas sensitization of central nociceptive pathways seems to contribute to the process of CTTH.
Research has implicated myofascial activity as a potential source of TTH whereby persistent activation of trigger points might lead to peripheral nociceptor sensitization and eventual sensitization of second-order neurons in the spinal trigeminal nucleus. 23 A number of studies have demonstrated increased levels of pericranial and cervical muscle tenderness in patients with TTH when compared to controls. This tenderness has also been correlated directly with both frequency and intensity measures of headache. Because this abnormality has been detected on headache-free days as well as headache days, it is speculated that this represents a cause rather than an effect of headache occurrences. A series of blinded controlled studies have documented increased numbers of active and latent trigger points in patients with TTH when compared to controls, and these were associated with neck mobility and forward head posture as well as the severity of the headache disorder. 24 Although EMG-measured pericranial muscle activity is not diffusely elevated in populations of TTH patients, it has been reported that EMG activity is increased in specific trigger points of these muscles. Some have proposed that continuous activity in a selection of motor units over a sustained period of time might excite peripheral nociceptors, perhaps through direct mechanical means, local ischemia, or release of inflammatory mediators. 25 Although research has documented deficiencies in exercise-induced increases in pericranial muscle tissue, microdialysis techniques have not yet demonstrated subsequent increased levels of lactate or inflammatory mediators in these muscles. 26 Central mechanisms appear to be more relevant to the pathogenesis of CTTH 27 (Case 6-2). Pain thresholds have been shown to be normal in infrequent ETTH but decreased in frequent ETTH and CTTH. Patients with CTTH have been found to be hypersensitive to stimulation via pressure, thermal, and electrical modalities as well as to IM infusion of noxious substances. These sensitivities have been shown in a number of tissues (muscle, tendon, nerve) both during and between headaches and at cephalic and extracephalic sites. 28 Population-based studies have demonstrated a relationship between increased pain sensitivity and transformation from episodic to chronic headaches (''chronification'') KEY POINT h Pericranial myofascial mechanisms are probably of importance in episodic tension-type headache, whereas sensitization of central nociceptive pathways seems to contribute to the process of chronic tension-type headache. and increased prevalence of TTH. 29 Research has also documented deficient central nociceptive inhibitory pathways in patients with CTTH. Using voxelbased morphometry, brain MRI scans of patients with CTTH have displayed significantly reduced density of gray matter structures along the pain matrix, including the dorsal rostral and ventral pons, the cingulate and insular and orbitofrontal cortex, the right posterior temporal lobe, the parahippocampus bilaterally, and the right cerebellum. 30 This decrease in gray matter correlated positively with increasing headache duration in years.
MANAGEMENT OF TENSION-TYPE HEADACHE
The approach to the management of TTH involves a combination of lifestyle, physical, and pharmacologic measures. 31 Nonpharmacologic management should always be considered, although the scientific evidence is limited. Recommendations for regulation of sleep, meals, and exercise are generally quite valuable. Stress management techniques and other steps toward trigger avoidance may be of great benefit. Passive physical manipulation and active cervical muscle stretching or exercise programs are often advised. Behavioral therapies are
Case 6-2
A 52-year-old man reported having headaches every day for the past 3 years. He was otherwise healthy and had no history of head or neck trauma. He recalled having ''regular headaches'' since his college years that were generally mild to moderate in intensity and without noticeable disability. These lasted a few hours and resolved spontaneously after dosing with simple analgesics. Throughout his forties the episodes escalated in frequency from monthly to several times per week, as did his analgesic intake. Over the past 3 years the headaches occurred daily, and he described them as a constant bilateral frontotemporal pressure sensation that is mild upon awakening but escalates to moderate intensity as the day progresses. Occasionally he experienced modest phonophobia, but he denied photophobia, nausea, neck pain, or neurologic features. Simple analgesics became ineffective ''years ago,'' and he no longer treated with any acute medication. General and neurologic examinations and brain MRI were normal.
Comment. This case describes a classic case of chronic tension-type headache. The long-standing history of a nondisabling headache disorder that gradually transforms from an episodic form to a daily or near-daily one is quite characteristic for chronic tension-type headache. The long-standing history and normal examinations and brain MRI render additional testing for secondary headache unnecessary. Other primary headache syndromes can present with constant daily discomfort but may be excluded here because of the bilateral location of the pain (excludes hemicrania continua), the gradual transition into daily headache (excludes new daily persistent headache), and the absence of nausea or photophobia (excludes chronic migraine). Both nonpharmacologic and pharmacologic preventive strategies should be used. A trial of a prescription-strength nonsteroidal anti-inflammatory drug or a caffeine-containing compound for acute episodes may be worthwhile, but their use should be strictly limited to 10 treatment days per month to avoid the development of a medication-overuse component.
useful adjuncts in the management of episodic TTH; the most frequently recommended techniques are relaxation therapy and EMG-guided biofeedback. Cognitive-behavioral therapy may provide additional benefit in patients with significant depression or anxiety. A recent set of guidelines published by the European Federation of Neurological Societies (EFNS) assessed the evidence for nondrug treatments of TTH ( Table 6 -3). 32 TTH is typically managed mainly through administration of medication during acute episodes. Typical analgesic remedies may be obtained over-thecounter or by prescription, and evidence is available to recommend a number of options ( Table 6 -4) . 32 Simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and combination agents are most commonly recommended. Many controlled studies have documented the efficacy of these agents in episodes of TTH. Their use should be strictly limited to an average of 2 to 3 days per week to avoid medication-overuse headache and potential contribution toward transformation into CTTH.
Aspirin is more effective than placebo and comparable to the efficacy of acetaminophen in the relief of acute TTH. Given their superior efficacy in comparative trials, NSAIDs are generally considered the drugs of choice for acute TTH. Ibuprofen and naproxen sodium are listed as first-line agents in the NSAID category because of better gastrointestinal tolerability. Caffeinecontaining compounds may be useful in patients who do not respond to simple or NSAID analgesics because the addition of caffeine (130 mg to 200 mg) has been shown to significantly increase the efficacy of simple analgesics and ibuprofen in controlled clinical trials. Triptans and muscle relaxants have not demonstrated consistent superiority over placebo in clinical trials of ETTH and are not recommended. Butalbital-containing compounds may be helpful in those patients who have contraindications to first-line analgesics or those for whom these analgesics have been ineffective. However, such drugs must be used with caution and their supplies limited because of an elevated risk of medication-overuse headache. Given the low levels of pain severity and disability associated with TTH and the high risk for developing medicationoveruse headache, opioid analgesics are not recommended for the management of TTH.
Preventive pharmacologic therapy is generally advised for those patients experiencing at least 2 to 3 headache days each week. 33 Although analgesics may KEY POINTS h The approach to the management of tension-type headache involves a combination of lifestyle, physical, and pharmacologic measures.
h Given their superior efficacy in comparative trials, NSAIDs are generally considered the drugs of choice for acute tension-type headache. continue to be beneficial when taken at such levels, the issues of medicationoveruse headache and transformation into more refractory cases of CTTH must be considered. Progression in frequency or severity of attacks, development of adverse events with acute medications, and decline in efficacy of acute medications may be additional indications for the institution of daily pharmacologic preventive therapy. These agents should be initiated at low doses and gradually increased based on efficacy and tolerability. Once an effective dose is reached, treatment is typically continued for 6 to 12 months, at which point daily medication may be tapered and the patient followed clinically. Although little well-controlled scientific evidence supports their use, most clinicians recommend antidepressants and anticonvulsants to help stabilize TTH 33 (Case 6-3) . Few controlled studies have been performed, with only some demonstrating superior efficacy to placebo. The data for the tricyclic antidepressant amitriptyline are most convincing, and clomipramine, nortriptyline, and doxepin may be useful alternatives if amitriptyline is poorly tolerated. Protriptyline has been reported to be helpful in CTTH, and unlike other tricyclic antidepressants its use may be associated with weight stability or reduction. Most studies with amitriptyline begin at doses of 10 mg to 25 mg nightly, with an average final dose of 50 mg to 75 mg nightly for patients with CTTH. Studies of selective serotonin reuptake inhibitors have shown no superiority over placebo. The serotoninnorepinephrine reuptake inhibitors mirtazapine and extended-release venlafaxine have been shown to be beneficial in single clinical trials. The centrally acting muscle relaxant tizanidine has shown efficacy in a crossover clinical trial. All data on anticonvulsants are from open-label studies, and the results have been mixed. OnabotulinumtoxinA appeared to be helpful for CTTH in a few small open-label reports, but this benefit was not confirmed by a series of double-blind placebo-controlled studies. 34 Two recent meta-analyses arrived at opposite conclusions, with one demonstrating benefit and the other a lack of benefit for prophylactic drugs for TTH in adults. 35, 36 The EFNS guidelines have listed a number of agents deemed effective by available data or expert consensus ( older adults. 37 In a study of adult outpatients with TTH followed over 10 years, 44% of those with CTTH reported significant improvement or com-plete resolution, whereas 29% of those with ETTH converted to CTTH. 38 A 2-year follow-up from a Danish crosssectional population study revealed a 
Case 6-3
A 32-year-old mother of three children presented with ''bad headaches'' and requests for ''a brain scan and better headache medicine.'' She had a history of postpartum depression responsive to sertraline, but she discontinued the medication 1 year ago because of fatigue. Her headaches began after the birth of her first child 7 years ago. After the birth of her third son 18 months ago they increased in frequency and intensity. She reported that since that time she was experiencing two to three episodes of headache each week lasting ''most of the day.'' The pain seemed to begin without warning sign or direct trigger, although she felt that the episodes were perhaps more common during menses or stressful times each month. Initial bitemporal tightness evolved into holocranial heaviness over the span of several hours. She did not have photophobia, phonophobia, or nausea. Acetaminophen 500 mg helped to reduce but not eliminate the pain. Her depression was described as moderate, and although she and her children slept through the night, she reported a constant sense of fatigue. General and neurologic examinations were normal. Comment. This case involves a presentation of frequent episodic tension-type headache. Given the stability of the pattern for 18 months, a history typical for episodic tension-type headache, and a normal examination, there is no absolute indication for diagnostic imaging. The presence of fatigue and depression may warrant serum testing for anemia or thyroid dysfunction. Noting a headache frequency of 8 to 12 days per month, it is certainly reasonable to consider both nonpharmacologic and pharmacologic preventive options, and in the presence of depression one of the antidepressant agents would seem most likely to be helpful. Amitriptyline has the best evidence of success for tension-type headache prophylaxis, but it may not be the best choice because of its sedative qualities and her report of normal sleep and constant fatigue. Extended-release venlafaxine may be a sensible option, and a nonsteroidal anti-inflammatory drug analgesic such as ibuprofen or naproxen sodium should be recommended for acute attacks.
45% remission rate among those with frequent ETTH or CTTH, whereas 39% continued to report ETTH and 16% CTTH. Poor outcome in TTH was associated with the following variables: CTTH at baseline, coexisting migraine or sleep difficulties, and being unmarried. In this study older age (mean 57 years versus 53 years) was reported as a positive predictive factor for remission. 39 CONCLUSIONS TTH is the most common headache in the general population. Because of extensive symptom overlap with secondary headache disorders and migraine, the diagnosis of TTH requires exclusion of these other conditions. The diagnosis is based on clinical criteria, and TTH is broadly divided into episodic (fewer than 15 days per month) and chronic (15 days or more per month) subtypes. Although attacks of TTH are generally less disabling than those of migraine, work absences are common, and the total societal burden appears to exceed that of migraine because of the high prevalence of TTH. Pericranial myofascial mechanisms are probably of importance in ETTH, whereas sensitization of central nociceptive pathways and inadequate endogenous antinociceptive circuitry seem to be more relevant in CTTH. While acute therapy with simple and NSAID analgesics is typically effective for the treatment of episodes of ETTH, CTTH is often more difficult to manage. Although there is little scientific evidence to guide the selection of treatment modalities in CTTH, most specialists advise a combination of nonpharmacologic and pharmacologic therapies. The prognosis of TTH is generally favorable, with limited disability during headache occurrences and age-related improvement or resolution of episodes later in life. h Remission of tension-type headache is positively affected by older age and negatively impacted by the presence of chronic tension-type headache at baseline, coexisting migraine or sleep difficulties, and being unmarried.
